Many biotechnology companies raised new venture capital in 2015 within months of registering with the US Securities and Exchange Commission (SEC) to launch an initial public offering, but the trend seems to have reversed course in 2016.
Biotech firms seemed determined last year to send a signal to potential IPO investors that they were well-financed even without...